Abstract

The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has dramatically influenced various aspects of the world. It is urgent to thoroughly study pathology and underlying mechanisms for developing effective strategies to prevent and treat this threatening disease. It is universally acknowledged that cell death and cell autophagy are essential and crucial to maintaining host homeostasis and participating in disease pathogenesis. At present, more than twenty different types of cell death have been discovered, some parts of which have been fully understood, whereas some of which need more investigation. Increasing studies have indicated that cell death and cell autophagy caused by coronavirus might play an important role in virus infection and pathogenicity. However, the knowledge of the interactions and related mechanisms of SARS-CoV-2 between cell death and cell autophagy lacks systematic elucidation. Therefore, in this review, we comprehensively delineate how SARS-CoV-2 manipulates diverse cell death (including apoptosis, necroptosis, pyroptosis, ferroptosis, and NETosis) and cell autophagy for itself benefits, which is simultaneously involved in the occurrence and progression of COVID-19, aiming to provide a reasonable basis for the existing interventions and further development of novel therapies.

Details

Title
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
Author
Li, Xue 1 ; Zhang, Ziqi 2 ; Wang, Zhenling 3 ; Gutiérrez-Castrellón, Pedro 4   VIAFID ORCID Logo  ; Shi, Huashan 1 

 Sichuan University, Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 Sichuan University, Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 Sichuan University, and Collaborative Innovation Center of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 Center for Translational Research on Health Science, Hospital General Dr. Manuel Gea Gonzalez. Ministry of Health, Mexico city, Mexico (GRID:grid.415745.6) (ISNI:0000 0004 1791 0836) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2675830338
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.